23andMe Founder and Board Member Anne Wojcicki speaks throughout a Home Committee on Oversight and Authorities Reform listening to on June 10, 2025 in Washington, DC.
Andrew Harnik | Getty Photographs
Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained management over the embattled genetic testing firm after her new nonprofit, TTAM Analysis Institute, out bid Regeneron Prescribed drugs, the corporate introduced on Friday.
TTAM will purchase considerably all of 23andMe’s property for $305 million, together with its Private Genome Service and Analysis Providers enterprise strains in addition to telehealth subsidiary Lemonaid Well being. It is a huge win for Wojcicki, who stepped down from her function as CEO when 23andMe filed for for Chapter 11 chapter safety in March.
Final month, Regeneron introduced that it will buy most of 23andMe’s property for $256 million after it got here out on high throughout a chapter public sale. However Wojcicki submitted a separate $305 million bid by way of TTAM and pushed to reopen the public sale. TTAM is an acronym for the primary letters of 23andMe, based on the Wall Road Journal.
“I’m thrilled that TTAM Analysis Institute will be capable of proceed the mission of 23andMe to assist individuals entry, perceive and profit from the human genome,” Wojcicki stated in a press release.
23andMe gained reputation due to its at-home DNA testing kits that gave clients perception into their household histories and genetic profiles. The five-time CNBC Disruptor 50 firm went public in 2021 through a merger with a particular objective acquisition firm. At its peak, 23andMe was valued at round $6 billion.
The corporate struggled to generate recurring income and get up viable analysis and therapeutics companies after going public, and it has been suffering from privateness issues since hackers accessed the knowledge of almost 7 million clients in 2023.
TTAM’s acquisition continues to be topic to approval by the U.S. Chapter Court docket for the Japanese District of Missouri.